๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Suzhou
Clinical trial register · China

Clinical Trials in Suzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Suzhou 20 Hangzhou 18 Beijing 14 Tianjin 14 Shanghai 10
Narrow the registerReset
Recruitment status
Phase
Site location
Suzhou20 Hangzhou18 Beijing14 Tianjin14 Shanghai10
All 41 locations
Target enrolment
to

Trials with a site in Suzhou

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
VA Consolidation in Intermediate-Risk AML
NCT07672262Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
The First Affiliated Hospital of Soochow University
Phase 2
226
Suzhou
2026-06-01
Not yet open
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
NCT07575412Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
180
Suzhou
2026-06
Not yet open
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
NCT07562568Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
160
Suzhou
2026-06
Recruiting
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
NCT07425782Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk
The First Affiliated Hospital of Soochow University
Phase 2
216
Suzhou
2026-02-01
Recruiting
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
NCT07007949Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib
The First Affiliated Hospital of Soochow University
Phase 2
42
Suzhou
2025-06-01
Recruiting
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
NCT06816134Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
The First Affiliated Hospital of Soochow University
Phase 2
48
Suzhou
2025-01-30
Recruiting
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
NCT06746519Acute Myeloid Leukemia
Chen Suning
Phase 1/2
135
Suzhou
2024-12-25
Recruiting
VA vs DA for Newly Diagnosed Hig-risk AML
NCT05939180Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2/3
116
Suzhou
2024-04-01
Recruiting
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
NCT06234904Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1
18
Suzhou
2024-03-26
Recruiting
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
NCT06220162Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
32
Suzhou
2024-02-01
Active, closed
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFฮฒ::MYH11(+) AML
NCT06429098Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2024-01-01
Recruiting
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
NCT06221683AML, Childhood, Acute Myeloid Leukemia
Children's Hospital of Soochow University
Phase 2
500
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-01-01
Recruiting
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT05991908Acute Myeloid Leukemia, Myelodysplastic Syndromes
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Recruiting
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
NCT05772273Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2023-03-15
Recruiting
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
NCT05805098Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2/3
60
Suzhou
2023-03-01
Recruiting
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
198
Nanchang, Suzhou, Zhengzhou
2023-02-14
Recruiting
CAV Regimen for R/R AML
NCT05657639Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
68
Suzhou
2022-10-01
Active, closed
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05029141Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML
The First Affiliated Hospital of Soochow University
Phase 2
21
Suzhou
2021-09-01
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Active, closed
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
NCT06379360Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
60
Suzhou
2019-07-01
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/suzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Suzhou that also match the filters currently applied.

How many clinical trials are recruiting in Suzhou?

15 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suzhou), 20 studies
PhaseStudiesRecruitingShare
Phase 212760%
Phase 12210%
Phase 1/22210%
Phase 2/32210%
Not applicable115%
Phase 3115%

Most active sponsors

Lead sponsors with the most studies (Suzhou)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Soochow University149
BeOne Medicines11
Chen Suning11
Children's Hospital of Soochow University11
Guangzhou Lupeng Pharmaceutical Company LTD.11
Imbioray (Hangzhou) Biomedicine Co., Ltd.11
Shanghai Jiao Tong University School of Medicine11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.